Company Profile
Agenus Stock Price, News & Analysis
- Ticker:
- AGEN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.49 USD (-3.73%)
Close
Last updated: August 6, 2026
141M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AGEN closed down 3.73% at $7.49. No new same-company headline was identified in the current news window.
Company overview
Business overview
Agenus is an immuno-oncology company focused on cancer immunotherapy, including checkpoint and combination approaches. The company has spent years trying to turn immune science into a durable oncology franchise.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Agenus sits in specialty oncology biotechnology.
Business Model Characteristics
The business depends on clinical data, strategic partnerships, and the ability to translate immunotherapy science into value.
Position Within the Biotechnology Landscape
Agenus is a high-risk oncology name whose valuation is heavily dependent on clinical and strategic milestones.
Future catalysts
Agenus's catalysts are botensilimab and balstilimab combination data, plus any partnering progression that can de-risk the program. The company still needs proof that the immuno-oncology story can keep moving.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Agenus (AGEN)?
Agenus (AGEN) most recently closed at 7.49 USD, a -3.73% move versus the previous session.
What is the market cap of Agenus (AGEN)?
Agenus currently has a market capitalization of 141M USD on BioPharmSignal.
What does Agenus do?
Agenus is an immuno-oncology company focused on cancer immunotherapy, including checkpoint and combination approaches. The company has spent years trying to turn immune science into a durable oncology franchise.
On which exchange is AGEN stock listed?
Agenus (AGEN) is associated with NASDAQ, United States, Biopharma.
What is botensilimab?
Agenus's catalysts are botensilimab and balstilimab combination data, plus any partnering progression that can de-risk the program.
Which conditions is Agenus targeting with botensilimab?
Agenus is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Agenus describe recent progress with botensilimab?
Agenus's catalysts are botensilimab and balstilimab combination data, plus any partnering progression that can de-risk the program.
What is balstilimab?
Agenus's catalysts are botensilimab and balstilimab combination data, plus any partnering progression that can de-risk the program.